With launch time potentially approaching for TrumpRx, HHS unveiled part of its plan to shield drugmakers from anti-kickback laws to allow them to sell their products on the new direct-to-consumer platform. The guidance — released via …
Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs
A biotech led by former Merck top brass with a pipeline anchored by three cancer drugs linked to Chinese drug developers is pushing ahead with an IPO, even while off its peak valuation. Eikon Therapeutics …
Included Health launches alternative health plan
Included Health, the virtual care and navigation company, is now offering a health plan for employers. It’s new territory for the startup, and the move puts it in a league with companies such as Centivo …
Hengrui blazes trail as Chinese drugmakers aspire to go multinational
Jiangsu Hengrui Pharmaceuticals has quietly become a top 25 biopharma company in the world by market value. Once virtually unknown outside of China, the company has made its name overseas via an R&D engine that …
What AI “remembers” about you is privacy’s next frontier
The ability to remember you and your preferences is rapidly becoming a big selling point for AI chatbots and agents. Earlier this month, Google announced Personal Intelligence, a new way for people to interact with the company’s Gemini chatbot that draws on their Gmail, photos, search, and YouTube histories to make Gemini “more personal, proactive, […]
Halozyme buys drug delivery biotech Surf Bio; Sanofi backs Sensorion
Post Content
Surging Cyberattacks Boost Latin America to Riskiest Region
The region is up against tactics like data-leak extortion, credential-stealing campaigns, edge-device exploitation, and attackers leveraging AI.
Rules fail at the prompt, succeed at the boundary
From the Gemini Calendar prompt-injection attack of 2026 to the September 2025 state-sponsored hack using Anthropic’s Claude code as an automated intrusion engine, the coercion of human-in-the-loop agentic actions and fully autonomous agentic workflows are the new attack vector for hackers. In the Anthropic case, roughly 30 organizations across tech, finance, manufacturing, and government were […]
Lilly allies with gene-editing firm Seamless on hearing loss
Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.
Boehringer drug scores in rare kidney disease FSGS
Boehringer’s TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.
Biopharma Sentiment Index | Q1 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric. After four years of hunkering down, the mood in biopharma turned sharply more optimistic heading into 2026. The Biopharma Sentiment Index (BPSI) climbed to 90 in Q1, up from 78 the prior quarter — a broad-based […]
Cellares raises $257M to fund global expansion as it eyes 2027 IPO
Clinical-stage cell therapy manufacturer Cellares has raised $257 million in a Series D round as it gears up commercially and prepares to go public. Cellares aims to launch its commercial cell therapy manufacturing services in …